Department of Respiratory and Critical Care Medicine, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
PLoS One. 2021 Nov 12;16(11):e0259784. doi: 10.1371/journal.pone.0259784. eCollection 2021.
Current studies showed that idiopathic pulmonary fibrosis (IPF) may lead to a poor prognosis of lung cancer. We conducted a meta-analysis to explore the impact of concomitant IPF in lung cancer and its prognostic value.
We searched the databases of PubMed, Web of Science, Embase up to Feb 10th, 2021 for relevant researches and merged the hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the association between concomitant IPF and overall survival (OS) in patients with lung cancer.
Twelve studies involving 58424 patients were included in our meta-analysis. The results indicated that concomitant IPF was correlated with poor prognosis of lung cancer patients (HR = 1.99, 95%CI, 1.59-2.51). The association remained consistent after subgroup analysis and meta-regression stratified by study region, sample size, tumor histology, and therapy. In addition, our results were robust even after sensitivity analysis.
Concomitant IPF may be a prognostic factor of lung cancer, which can lead to poor survival. However, further studies were necessary for evidence in clinical application.
目前的研究表明，特发性肺纤维化（IPF）可能导致肺癌预后不良。我们进行了一项荟萃分析，以探讨肺癌合并特发性肺纤维化的影响及其预后价值。
我们检索了 PubMed、Web of Science、Embase 数据库，检索时间截至 2021 年 2 月 10 日，以评估合并特发性肺纤维化与肺癌患者总生存期（OS）之间的相关性。
共有 12 项研究纳入了 58424 例患者。结果表明，合并特发性肺纤维化与肺癌患者的预后不良相关（HR=1.99，95%CI，1.59-2.51）。通过研究区域、样本量、肿瘤组织学和治疗的亚组分析和荟萃回归分层，该相关性仍然一致。此外，即使进行敏感性分析，我们的结果也是稳健的。
合并特发性肺纤维化可能是肺癌的预后因素，可导致生存不良。然而，进一步的研究对于临床应用的证据是必要的。
